Basic Efavirenz Information

• INN (International Nonproprietary Name): Efavirenz.
• Brand Names Available In Canada (English): Sustiva and Atripla; typically as 600mg tablet and 200mg capsule; supplied by BMS Canada and Gilead Sciences in blister packs.
• ATC Code: J05AG03.
• Forms & Dosages: Tablets 600mg and 200mg; capsules 50mg (pediatric) and 200mg; fixed‑dose Atripla contains 600mg efavirenz + 200mg emtricitabine + 300mg tenofovir disoproxil fumarate.
• Manufacturers In Canada (English): Bristol‑Myers Squibb (originator) and generic suppliers available globally include Teva and Mylan; local distribution via BMS Canada and Gilead for combinations.
• Registration Status In Canada (English): Registered and marketed; approved for HIV‑1 treatment as part of combination ART with assigned DINs for marketed presentations.
• OTC / Rx Classification: Prescription only (Rx).

Major 2022–2025 Canadian & Global Studies

Main Outcomes

Clinicians want to know if efavirenz still controls HIV effectively compared with newer agents.

Recent cohort meta‑analyses and Canadian clinic registries from 2022–2025 confirm efavirenz 600 mg remains virologically effective when used in combination ART.

Comparative effectiveness research shows integrase inhibitor regimens, particularly dolutegravir, increasingly replace efavirenz because of improved tolerability and similar or superior suppression kinetics.

The ENCORE1 lower‑dose hypothesis (400 mg) continues to influence dosing debates and practice patterns.

Pharmacokinetic reconfirmation studies from 2022–2024 support non‑inferiority of reduced‑dose strategies in select populations, though Health Canada labelling remains centred on 600 mg.

Canadian registries report that many regimen changes are driven by tolerability rather than virologic failure.

Safety Observations

Safety surveillance from 2022–2025 highlights persistent central nervous system adverse events as the most prominent issue.

Reports indicate vivid dreams, insomnia, dizziness and mood disturbances occur more often with efavirenz than with integrase inhibitors.

Neuropsychiatric switch rates are higher for efavirenz in real‑world Canadian clinic data.

Pregnancy and teratogenicity signals remain under active review with registry updates through 2024 advising contraception counselling and a careful risk/benefit discussion for women of child‑bearing potential.

Overall evidence level rates high for effectiveness and moderate‑high for safety trends.

Layman’s Explanation

Scientific Breakdown

People often ask, "How does efavirenz stop HIV?"

Efavirenz is an NNRTI that blocks HIV‑1 reverse transcriptase and prevents the virus from copying its RNA into DNA.

The drug is taken once daily and is used with two NRTIs to form a standard combination ART regimen like Atripla.

At the molecular level efavirenz binds a hydrophobic pocket of HIV‑1 reverse transcriptase distinct from the NRTI binding site.

This causes allosteric inhibition and conformational distortion that impairs polymerase activity and viral replication.

Oral bioavailability increases with food, especially high‑fat meals, and peak plasma levels occur within three to five hours.

Efavirenz has a long half‑life of roughly 40–55 hours, which supports once‑daily dosing.

Hepatic metabolism is primarily via CYP2B6 and CYP3A4, and genetic polymorphisms such as CYP2B6*6 can raise exposure and CNS side effects in some patients.

Clinically this means predictable potency but a safety profile dominated by CNS and hepatic monitoring needs.

Health Canada Approvals (DIN-Based)

Notable Off-Label Trends In Canadian Practice

Health Canada lists efavirenz as an approved antiretroviral for HIV‑1 treatment when used in combination regimens.

Marketed brand names in Canada include Sustiva and the fixed‑dose combination Atripla, each with assigned DINs for specific presentations.

Local product labels and monographs specify adult and paediatric dosing, and clinicians refer to DINs for formulary claims and substitutions.

Off‑label trends in Canada include selective use of reduced‑dose efavirenz (400 mg) based on ENCORE1 legacy data and later reconfirmation PK studies.

Some HIV specialists consider 400 mg off‑label for patients with tolerability issues, after counselling and specialist review.

Efavirenz is occasionally used for PEP in constrained supply situations, with careful monitoring and combination therapy for 28 days.

Provincial formularies vary and many now favour dolutegravir‑based first‑line coverage, which affects how often efavirenz is prescribed in practice.

General Dosing Per Health Canada Monographs

Condition-Specific Dosing Adjustments

Standard adult dosing per Health Canada is 600 mg orally once daily, usually taken on an empty stomach or with a light meal depending on tolerability guidance.

The WHO Defined Daily Dose for efavirenz is 0.6 g per day.

Paediatric dosing is weight‑band based with 50 mg capsules or 200 mg and 300 mg tablet options; patients ≥35 kg often receive 600 mg daily.

For hepatic impairment avoid efavirenz in moderate to severe dysfunction and monitor LFTs closely in mild cases.

No routine renal dose adjustment is required for mild to moderate kidney disease, but use clinical judgement in severe renal impairment due to limited data.

Pregnancy counselling is important because of teratogenicity concerns; avoid efavirenz in women of child‑bearing potential unless reliable contraception is used.

Genetic CYP2B6 slow‑metaboliser genotypes increase plasma levels and CNS adverse events, so therapeutic monitoring or a regimen change may be needed for intolerant patients.

Efavirenz is sometimes chosen in PEP regimens as part of a 28‑day combination course when formulation availability directs therapy.

Contraindications (Canadian Advisories)

Adverse Effects (Post-Market Reports)

Known hypersensitivity to efavirenz or its excipients is an absolute contraindication.

Severe hepatic impairment is a contraindication and moderate dysfunction requires caution and monitoring.

Health Canada contraindications include co‑administration with drugs such as voriconazole, elbasvir/grazoprevir, and St. John’s Wort.

Women of child‑bearing potential must receive contraception counselling given pregnancy safety signals.

Common adverse effects reported in Canada and internationally centre on CNS symptoms: vivid dreams, insomnia, dizziness, impaired concentration, anxiety and depression.

Severe dermatologic reactions are rare but reported, including Stevens–Johnson syndrome.

Elevated liver enzymes and lipid abnormalities are documented in post‑market surveillance.

Clinical safety protocols recommend baseline and periodic LFTs and depression screening, plus prompt review of any rash or psychiatric symptoms.

In overdose, management is supportive and activated charcoal may be considered for recent ingestion.

Food Interactions Common In Canadian Diet

Drug Combinations Flagged By Health Canada

Efavirenz bioavailability increases with fatty meals, so consistent dosing with respect to food is advised to avoid peaks that worsen CNS effects.

Patients should avoid large high‑fat breakfasts or oily supplements at the time of dosing to reduce peak plasma concentrations.

Efavirenz is both a substrate and inducer of CYP enzymes, notably CYP3A4 and CYP2B6, generating many interactions.

Health Canada flags interactions with benzodiazepines like midazolam and triazolam, some antipsychotics, and ergot derivatives.

Hormonal contraceptives may have reduced efficacy when used with efavirenz, so alternative or additional contraception should be considered.

Herbal products such as St. John’s Wort are contraindicated because they lower efavirenz concentrations and risk treatment failure.

Clinicians should review community pharmacy records at chains such as Shoppers Drug Mart and Rexall to avoid dangerous combinations.

Consider CYP2B6 genotype‑informed care for patients of African descent or those with unexplained CNS toxicity, although routine therapeutic drug monitoring is uncommon in Canada.

Canadian Survey Data

Forum & Community Pharmacy Trends

Many patients in Canadian clinic surveys report vivid dreams and sleep disturbance soon after starting efavirenz.

A meaningful minority request regimen changes within three to six months due to tolerability issues.

Provincial HIV clinics link adherence challenges to CNS side effects when these are not promptly addressed.

Online forums and patient advocacy groups in Canada frequently mention Sustiva and Atripla by name and share tips to manage side effects.

Common practical advice includes taking efavirenz at bedtime and avoiding fatty meals at dosing to reduce peak‑related CNS effects.

Community pharmacies such as Shoppers, London Drugs and Jean Coutu report emphasising counselling on psychiatric adverse events and contraception at dispensing.

Pharmacist‑led follow‑up programmes in some provinces conduct early tolerability checks and can facilitate switches to dolutegravir where provincially funded formularies allow.

Patients often value once‑daily dosing but prefer agents with fewer CNS effects when given a choice.

National Pharmacy Chains

Online Pharmacy Availability & Provincial Restrictions

Efavirenz products, both branded and generic, are dispensed across major Canadian chains including Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs.

Hospital pharmacies also stock efavirenz for inpatient and outpatient HIV care teams.

Provincial drug plans such as Ontario Drug Benefit, BC PharmaCare and RAMQ list ARTs with variable reimbursement pathways and criteria.

Some formularies require specialist prescribing or prior authorization, which affects community access and dispensing workflows.

Licensed Canadian online pharmacies may dispense efavirenz with a valid prescription and standard verification practices.

In our online pharmacy, efavirenz is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Generic competition from Teva and Mylan has reduced retail prices compared with historic branded pricing in the United States.

For patients concerned about cost, pharmacists can advise on provincial assistance programs and manufacturer compassionate access options.

Comparison Table Of DIN-Approved Alternatives

Pros And Cons Checklist

Clinicians and pharmacists commonly consider dolutegravir‑based combinations such as Triumeq as first‑line alternatives to efavirenz.

Dolutegravir advantages include better tolerability, rapid viral suppression and a higher barrier to resistance.

Drawbacks with dolutegravir noted in surveillance include weight‑gain signals and pregnancy counselling nuances.

Rilpivirine offers a more favourable CNS profile than efavirenz but has limitations with high baseline viral load and interactions with acid‑reducing agents.

Etravirine can be useful in resistance‑guided therapy but involves more complex dosing and interaction management.

Choice factors include baseline viral load, resistance testing, pregnancy potential, psychiatric history, and drug–drug interactions.

Provincial formulary coverage and DIN availability may drive pragmatic switches between efavirenz and alternatives in Canadian practice.

Health Canada Approval Process

DIN And Bilingual Labelling Rules

Health Canada granted marketing authorizations for efavirenz formulations and maintains pharmacovigilance obligations for manufacturers.

Products on the Canadian market carry DINs that pharmacies use for claims, reimbursement and substitutions.

Canadian labelling rules require bilingual (English/French) monographs and patient leaflets, plus clear DIN, lot and expiry information on packaging.

Manufacturers must submit periodic safety updates, and Health Canada can issue advisories based on emerging signals.

Provincial formulary listings reference DINs for coverage decisions and pharmacy system updates on brand to generic switches.

Regulatory trends through 2022–2025 show formularies increasingly favouring integrase inhibitor first‑line regimens while maintaining efavirenz as an approved, accessible option.

Consolidated FAQ

Is efavirenz still approved and available in Canada?

Yes; Sustiva and Atripla are approved and marketed in Canada with Health Canada DINs, though availability and coverage depend on provincial formularies.

Will efavirenz interact with my birth control?

Efavirenz can reduce the effectiveness of hormonal contraceptives, so patients should discuss alternative or additional contraception with their prescriber and pharmacist.

What if I experience vivid dreams or depression?

Report symptoms promptly to your care team; taking efavirenz at bedtime can help, but persistent or severe CNS effects often lead to switching to another agent such as dolutegravir.

Can I get a lower 400 mg dose in Canada?

Some international evidence supports 400 mg dosing, but Health Canada labelling remains centred on 600 mg; discuss off‑label reduced dosing with an HIV specialist.

How is efavirenz covered by provincial drug plans?

Coverage varies by province and plan; pharmacists at chains like Shoppers or Rexall can help verify coverage and copay details for individual patients.

Visual Guide Suggestions

Infographics that help patients include a dosage flowchart from paediatric weight bands to the adult 600 mg once‑daily dose and a note on 400 mg evidence.

A provincial coverage map with clickable links to Ontario, BC and Quebec formularies helps patients find reimbursement rules and specialist restrictions.

Purchase channel icons for Shoppers Drug Mart, Rexall, Jean Coutu, London Drugs, hospital pharmacies and licensed online pharmacies clarify where prescriptions may be filled.

A safety checklist graphic with baseline LFTs, depression screening, pregnancy test/contraception counselling and interaction review makes counselling points memorable.

Design elements should respect bilingual labelling, accessible contrast and QR links to Health Canada monographs and provincial formularies.

Canadian Household Storage Guidelines

Cold-Chain Storage Where Applicable

Store efavirenz below 30°C and protect it from moisture and light in the original labelled packaging.

Keep medication out of reach of children and avoid storing in humid areas such as bathrooms.

For travel, carry efavirenz in original containers with prescription documentation and avoid leaving it in hot cars or direct sunlight.

No cold‑chain is required for standard efavirenz formulations, but insulated packaging is recommended if transit conditions expose the product to extreme heat or freezing.

Community pharmacies and hospital stores follow local policies to protect blister packs and bottles during distribution to remote and northern communities.

Advice From Canadian Pharmacists

Provincial Health Authority Guidance

Pharmacists advise taking efavirenz consistently at the same time each day, commonly at bedtime to reduce daytime CNS symptoms.

Start dosing away from heavy meals to limit peak concentrations that can aggravate side effects.

Review all prescription and OTC medications including herbal products like St. John’s Wort to avoid interactions.

Women of child‑bearing potential require contraception counselling before starting efavirenz, and pharmacists should coordinate with prescribers for shared decision making.

Provincial HIV treatment guidelines increasingly recommend integrase inhibitor‑based first‑line regimens but retain efavirenz as an option where indicated.

Pharmacists at community chains frequently perform early follow‑up calls during the first month to assess tolerability and adherence and facilitate specialist referrals for switches if needed.

Delivery Across Canada (English)

Final Considerations For Patients And Clinicians

Efavirenz remains a potent NNRTI option with established efficacy as part of combination ART and inclusion on WHO essential medicine lists.

Choice of efavirenz versus integrase inhibitors should weigh CNS tolerability, pregnancy plans, resistance profiles and provincial formulary coverage.

Baseline LFTs and mental health screening are practical safety steps before and during therapy.

Switching to dolutegravir is common in Canadian practice for patients who experience persistent CNS effects on efavirenz.

Pharmacists and HIV specialists should collaborate on drug interaction checks, contraception counselling and early follow‑up to protect adherence and viral suppression.

For cost or access questions, community pharmacists can check DINs and provincial formularies and advise on generic options from Teva or Mylan.

Patients with severe psychiatric history or seizure disorders need close monitoring or alternative regimens due to relative contraindications.

Remember that efavirenz is effective when used correctly, but modern practice often prefers integrase inhibitor alternatives for better tolerability profiles.